Zai Lab Limited
A biopharmaceutical company that develops and brings to market medicines for cancer, immunology, neuroscience, and infectious disease, with a presence in both China and the United States. Founded in 2014 by Dr. Samantha Du, often called the 'godmother of China's biotech industry,' it was built to bring global medical innovations to Chinese patients faster. Its name comes from the Chinese character 'zài' (在), meaning 'to be' or 'to exist' — a nod to being present in patients' lives.
American Depositary Receipt
Granted 1.61M · Sold 433.8K
Granted 22.4K
Granted 22.4K
Granted 45.6K · Bought 10.0K · Sold 14.6K
Granted 22.4K
Granted 22.4K
Granted 22.4K · Bought 1.7K
Granted 22.4K
Granted 51.2K · Sold 36.4K
Granted 22.4K
Granted 22.4K · Sold 7.0K
Granted 29.7K · Sold 11.0K
Granted 41.1K · Sold 52.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Du YingChairperson & CEO, Director · 38 transactions | +104.5% | 1.19M | 1.61M | — | 433.8K |
| Wirth PeterDirector · 1 transaction | +5.7% | 416.1K | 22.4K | — | — |
| Diekman John DDirector · 1 transaction | +22.4% | 122.1K | 22.4K | — | — |
| Smiley Joshua LSee Remarks · 7 transactions | +53.5% | 117.6K | 45.6K | 10.0K | 14.6K |
| Leung NisaDirector · 1 transaction | +30.3% | 96.3K | 22.4K | — | — |
| Moulder Leon O JrDirector · 1 transaction | +30.8% | 95.0K | 22.4K | — | — |
| Gaynor RichardDirector · 2 transactions | +43.9% | 79.0K | 22.4K | 1.7K | — |
| Vounatsos MichelDirector · 1 transaction | +44.4% | 72.8K | 22.4K | — | — |
| Amado RafaelSee Remarks · 9 transactions | +35.2% | 57.0K | 51.2K | — | 36.4K |
| Morrison Scott WDirector · 1 transaction | +64.8% | 56.9K | 22.4K | — | — |
| Lis WilliamDirector · 2 transactions | +43.7% | 50.4K | 22.4K | — | 7.0K |
| Chen YajingChief Financial Officer · 14 transactions | +103.1% | 35.6K | 29.7K | — | 11.0K |
| Edmondson Frazor Titus IIIChief Legal Officer · 14 transactions | -27.9% | 30.3K | 41.1K | — | 52.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -544.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.